Research Article
Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma
Table 2
Multivariate logistic regression analysis.
| Group | Factor | Odds ratio | 95% confidence interval | p value |
| All patients | Ann Arbor staging (III and IV) | 2.09 | 0.84–5.24 | 0.118 | Bone marrow infiltration | 2.03 | 0.56–7.43 | 0.284 | Splenomegaly | 1.81 | 0.44–7.50 | 0.415 | Indolent lymphoma | 0.87 | 0.29–2.61 | 0.800 | Glucocorticoid use before rituximab infusion | 0.17 | 0.05–0.59 | 0.005 |
| Patients without glucocorticoid use before rituximab infusion | Ann Arbor staging (III and IV) | 1.94 | 0.73–5.18 | 0.185 | Bone marrow infiltration | 4.00 | 1.02–15.79 | 0.047 |
|
|